A new study is challenging the idea that the biological events driving Alzheimer’s-related brain damage are confined entirely to the brain. Researchers have found evidence that immune cells in other tissues may help activate T cells that later enter the brain and contribute to neurodegeneration linked to abnormal tau protein.
The research, published September 3 in Nature Neuroscience, was conducted primarily in mouse models of tauopathy. It points to conventional type 1 dendritic cells, or cDC1s, as key players in a series of immune events that seem to worsen neuronal damage.
The findings do not mean Alzheimer’s disease begins outside the brain. Instead, they suggest that communication between the brain and the peripheral immune system may be more important to disease progression than previously understood.
Table of Contents
Researchers Trace a Key Immune Step Beyond the Brain
Alzheimer’s disease is best known for two characteristic brain abnormalities: amyloid-beta plaques and abnormal accumulations of tau protein.
Tau normally helps stabilise structures inside nerve cells. In Alzheimer’s and other tau-related disorders, however, the protein becomes abnormal and aggregates inside neurons. Greater tau burden is strongly associated with neuronal dysfunction, brain atrophy and worsening cognitive impairment.
Researchers have also increasingly found evidence of immune involvement. The new study focused on CD8-positive T cells, a type of immune cell that normally recognises and destroys infected or abnormal cells.
Scientists already knew that unusually high numbers of these T cells appeared in brain regions affected by tau-related degeneration. What remained unclear was how they were being activated before arriving there.
Dendritic Cells May Prepare T Cells for the Brain
The researchers investigated conventional type 1 dendritic cells, which specialise in presenting biological material, known as antigens, to CD8 T cells. This process can effectively switch T cells from a resting state into active immune cells capable of moving through the body and attacking their targets.
In the new experiments, researchers found evidence that secondary lymphoid tissues outside the central nervous system presented brain-derived antigens.
That finding suggests that an important stage in the disease-associated immune response may occur outside the brain. Dendritic cells may encounter or process material associated with the diseased brain and then activate T cells in peripheral tissues. Those activated cells can subsequently migrate into the brain, where they contribute to a damaging inflammatory response.
Removing Certain Immune Cells Protected Mice
To test the role of dendritic cells more directly, scientists studied tauopathy mice in which cDC1 cells were genetically depleted or unable to efficiently present antigens to CD8 T cells.
The results were striking. Mice lacking the relevant dendritic-cell activity showed substantially less accumulation of CD8 T cells in the brain. They also had reduced glial cell activation, which is closely involved in inflammatory responses in the central nervous system.
Most importantly, the animals experienced less neurodegeneration. The protective effect occurred even though tau pathology itself was still present.
That distinction is important because it suggests that abnormal tau alone may not determine the extent of neuronal damage that develops. The immune response triggered by that pathology could play a major role in determining its consequences.
Earlier Research Found T Cells Can Worsen Tau Damage
The latest findings build on previous work from researchers at Washington University School of Medicine in St. Louis. In a 2023 study published in Nature, scientists reported that T-cell infiltration into the brain could actively contribute to neurodegeneration in experimental tauopathy.
That research identified an interaction between T cells and microglia, the brain’s resident immune cells. Microglia normally perform essential functions such as clearing debris and responding to injury. In neurodegenerative disease, however, prolonged activation can cause them to adopt inflammatory states that may damage neurones.
Earlier experiments suggested that microglia and infiltrating T cells can reinforce each other, creating an inflammatory loop that worsens neurodegeneration. The new study extends that model by asking where those T cells are initially prepared for action.
Alzheimer’s May Involve a Brain-to-Body Immune Circuit
Taken together, the research points toward a more complicated biological pathway. Abnormal processes in the brain may release or expose antigens. Those materials may then reach lymphatic tissues, where dendritic cells present them to T cells. The activated T cells can travel back toward the central nervous system, enter the brain and interact with microglia and other cells.
If that model is confirmed, Alzheimer’s-related neurodegeneration may involve a feedback circuit between the brain and the wider immune system rather than an isolated process occurring behind the blood-brain barrier.
The idea fits with broader changes in neuroscience. Researchers increasingly view the immune system, lymphatic circulation, blood vessels and metabolism as important contributors to neurological disease. Alzheimer’s itself is also increasingly understood as a disorder involving several overlapping mechanisms rather than a single pathological trigger.
Why Lymphatic Tissues Could Become Treatment Targets
The discovery may eventually have implications for drug development. One of the greatest challenges in treating brain diseases is the blood-brain barrier, which prevents many substances in the bloodstream from entering brain tissue. A treatment targeting an immune process occurring outside the brain could help avoid some of those difficulties.
Researchers are particularly interested in identifying the lymphatic tissues in which brain-derived antigens are presented and determining whether specific immune signals can be interrupted without broadly suppressing the immune system.
That would be essential because dendritic cells and CD8 T cells play critical roles in fighting infections and identifying abnormal cells. Simply eliminating these immune populations would not be a practical treatment strategy. A future therapy would need to target the disease-related immune pathway with far greater precision.
Findings Remain Preclinical
Despite the potentially important implications, the results require considerable caution. The experiments were carried out largely in mice engineered to develop tau-related neurodegeneration. Animal models can reveal biological mechanisms, but they do not reproduce every feature of human Alzheimer’s disease.
Researchers have not yet shown that blocking dendritic-cell-mediated T-cell activation slows Alzheimer’s progression in people. They also do not yet fully understand which brain-derived antigens are most important, how they reach peripheral immune tissues or whether the same pathway operates at comparable strength in human disease.
The study should therefore not be interpreted as proof that Alzheimer’s originates in the lymph nodes or that peripheral immune activity is the primary cause of the condition.
According to the Alzheimer’s Association’s 2026 estimates, about 7.4 million Americans aged 65 and older are living with Alzheimer’s dementia, which calls for additional treatment strategies beyond those already aimed at amyloid and tau.
What Comes Next
The next stage will be to determine whether this immune pathway can be safely interrupted after disease processes are already established. That is a much more clinically relevant test than genetically preventing immune activity before severe degeneration develops.
Researchers will also need to establish whether similar dendritic-cell and T-cell interactions occur in people with Alzheimer’s and whether particular lymph nodes or immune signalling molecules can be targeted selectively. For now, the study does not overturn the central role of amyloid and tau in Alzheimer’s biology. Instead, it adds another layer to the picture.
The damaging consequences of tau accumulation may depend in part on how the immune system responds to signals from the brain. If that connection holds up in human studies, future Alzheimer’s treatments may eventually target not only what is happening inside the brain but also the immune machinery responding to it elsewhere in the body.
